News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medrad, Inc. Announces New Head of Interventional Business


3/29/2011 1:00:10 PM

WARRENDALE, Pa., March 29, 2011 /PRNewswire/ -- Today MEDRAD, INC. announced that Jack Darby has joined the company as vice president of MEDRAD Interventional. In his new role, Darby will act as general manager of both the diagnostic and therapeutic lines of the business on a global scale, and will also join MEDRAD's executive leadership team.

(Photo: http://photos.prnewswire.com/prnh/20110329/NE73380 )

(Logo: http://photos.prnewswire.com/prnh/20040309/MEDRADLOGO )

Darby brings almost 20 years of experience in the medical device industry to the role, with most of those years in the interventional cardiology space. He comes to MEDRAD from AGA Medical Corporation, where he most recently served as senior vice president of Global Marketing and Distributor Sales, gaining deep experience in the field of the structural heart. Prior to AGA, Darby spent over 15 years at Cordis, a Johnson & Johnson company, starting as an angiographic sales representative. His leadership ability, sales/marketing acumen and international experience ultimately resulted in his role as vice president of commercial operations and global stent marketing.

"Jack's broad base of experience in the interventional space and combination drug-device products will greatly complement our patient-focused goals for the interventional business," says MEDRAD President and CEO Sam Liang. "With the support of his leadership, we plan to extend our product innovation and customer satisfaction footprint within this growing, global market."

With manufacturing facilities in both Minneapolis, MN and Pittsburgh, PA, MEDRAD Interventional manufactures and markets segment-leading medical devices such as AngioJet® Thrombectomy Systems, MEDRAD Avanta® Fluid Management Injector Systems and catheters, Mark V ProVis® Angiographic Contrast Injectors, FETCH® Aspiration Catheters and the GuardDOG® Occlusion System.

About MEDRAD, INC.

MEDRAD, INC. develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the safe treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. MEDRAD is a two-time recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence (2003 and 2010). The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a business of Bayer HealthCare. More company information is available at www.medrad.com.

Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.

Forward-looking statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

SOURCE MEDRAD, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES